Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 4/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.33 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.33 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.33 |
| ▸ | B3GNT2 | Q9NY97 | 1/20 | 0.31 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.31 |
| ▸ | CPA1 | P15085 | 1/20 | 0.30 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.30 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4597963 | 0.86 | GRIA1 (0.33) | GRIA1GRIK1GRIA2GRIA4GRIA3 | |
| SCHEMBL6037197 | 0.83 | KDM3B (0.35) | GRIA1GRIK1GRIA2GRIA4GRIA3 | |
| SCHEMBL5282402 | 0.81 | GRIA1 (0.51) | GRIA1GRIK1GRIA2GRIA4GRIA3 | |
| SCHEMBL6537411 | 0.79 | KMO (0.36) | GRIA1GRIK1GRIA2GRIA4GRIA3 | |
| SCHEMBL16247195 | 0.78 | APAF1 (0.46) | GRIA1GRIK1B3GNT2 | |
| SCHEMBL5586325 | 0.75 | SLC9A1 (0.50) | GRIA1GRIA2GRIA4GRIA3B3GNT2 | |
| SCHEMBL667079 | 0.73 | ALDH1A1 (0.33) | GRIA1GRIK1 | |
| SCHEMBL2899641 | 0.73 | APEX1 (0.48) | GRIA1GRIA2GRIA4GRIA3 | |
| SCHEMBL28861793 | 0.73 | TSHR (0.43) | B3GNT2 | |
| SCHEMBL26779833 | 0.72 | CDK4 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 13579 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112105627-B | Unnatural base pair compositions and methods of use | 斯克利普斯研究所 | 2024-07-02 | — | — | CN | claimed |
| CN-117778530-A | Method for adding preset joint to 5' end of single-stranded DNA | 清华大学 | 2024-03-29 | — | — | CN | claimed |
| WO-2023196944-A2 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2023-10-12 | — | — | WO | claimed |
| US-20230235339-A1 | IMPORT OF UNNATURAL OR MODIFIED NUCLEOSIDE TRIPHOSPHATES INTO CELLS VIA NUCLEIC ACID TRIPHOSPHATE TRANSPORTERS | THE SCRIPPS RESEARCH INSTITUTE | 2023-07-27 | — | — | US | claimed |
| US-20230148152-A1 | METHOD OF SYNTHESIZING SINGLE-STRANDED NUCLEOTIDE SEQUENCE, BLOCKED NUCLEOSIDE TRIPHOSPHATES AND RELATED METHODS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-05-11 | — | — | US | claimed |
| CN-114761026-A | Compositions and methods for in vivo synthesis of non-native polypeptides | 斯克利普斯研究所 | 2022-07-15 | — | — | CN | claimed |
| WO-2021097437-A1 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2021-05-20 | — | — | WO | claimed |
| WO-2021072167-A1 | COMPOSITIONS AND METHODS FOR IN VIVO SYNTHESIS OF UNNATURAL POLYPEPTIDES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-04-15 | — | — | WO | claimed |
| CN-112105627-A | Non-natural base pair compositions and methods of use | 斯克利普斯研究所 | 2020-12-18 | — | — | CN | claimed |
| EP-3732187-A1 | UNNATURAL BASE PAIR COMPOSITIONS AND METHODS OF USE | The Scripps Research Institute (US) | 2020-11-04 | — | — | EP | claimed |
| WO-2015157555-A2 | IMPORT OF UNNATURAL OR MODIFIED NUCLEOSIDE TRIPHOSPHATES INTO CELLS VIA NUCLEIC ACID TRIPHOSPHATE TRANSPORTERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-10-15 | — | — | WO | claimed |
| US-8895719-B2 | Markers for pre-cancer and cancer cells and the method to interfere with cell proliferation therein | ANDES BIOTECHNOLOGIES S.A. (CL) | 2014-11-25 | — | — | US | claimed |
| US-20130149371-A1 | MARKERS FOR PRE-CANCER AND CANCER CELLS AND THE METHOD TO INTERFERE WITH CELL PROLIFERATION THEREIN | ANDES BIOTECHNOLIGIES S.A. (CL) | 2013-06-13 | — | — | US | claimed |
| US-20090227489-A1 | STAT3 Agonists and Antagonists and Therapeutic Uses Thereof | JOHNS HOPKINS UNIVERSITY (US) | 2009-09-10 | — | — | US | claimed |
| EP-1308511-A1 | Use of angiopoietin-like 1 and angiopoietin-like 2 nucleic acids and proteins for the treatment of blood-related disorders and defects in vasculature. | Mermaid Pharmaceuticals GmbH (DE) | 2003-05-07 | — | — | EP | claimed |
| EP-1295130-A2 | NIMR COMPOSITIONS AND THEIR METHODS OF USE | TRUSTEES OF TUFTS COLLEGE (US) | 2003-03-26 | — | — | EP | claimed |
| WO-2001070776-A2 | NIMR COMPOSITIONS AND THEIR METHODS OF USE | TRUSTEES OF TUFTS COLLEGE (US) | 2001-09-27 | — | — | WO | claimed |
| US-5998596-A | Inhibition of protein kinase activity by aptameric action of oligonucleotides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-07 | — | — | US | claimed |
| WO-1998042723-A9 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF NEUROPSYCHIATRIC DISORDERS | — | 1999-03-04 | — | — | WO | claimed |
| US-5486603-A | Oligonucleotide having enhanced binding affinity | GILEAD SCIENCES, INC. (US) | 1996-01-23 | — | — | US | claimed |